Amgen Inc.
Antibody Constructs for CLDN18.2 and CD3

Last updated:

Abstract:

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Status:
Application
Type:

Utility

Filling date:

2 Aug 2019

Issue date:

20 Feb 2020